GW590735
Modify Date: 2025-09-11 13:30:05
GW590735 structure
|
Common Name | GW590735 | ||
|---|---|---|---|---|
| CAS Number | 343321-96-0 | Molecular Weight | 478.48 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C23H21F3N2O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GW590735GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia[1]. |
| Name | GW 590735 |
|---|---|
| Synonym | More Synonyms |
| Description | GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia[1]. |
|---|---|
| Related Catalog | |
| In Vivo | GW 590735 (0.5-5 mg/kg; orally twice a day for 5 days) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol in the Apo-A-I-transgenic mouse model (male C57BL/6 mice transgenic for human ApoA-I)[1]. GW 590735 (intravenous administration; 2.7 mg/kg; rat) treatment shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively[1]. GW 590735 (intravenous administration; 2 mg/kg; dog) treatment shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C23H21F3N2O4S |
| Molecular Weight | 478.48 |
| Exact Mass | 478.117401 |
| LogP | 5.22 |
| Index of Refraction | 1.572 |
| MFCD12912339 |
| 2-Methyl-2-(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}carbonyl)amino]methyl}phenoxy)propanoic acid |
| 2-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid |
| Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- |
| GW 590735 |
| GW-590735 |
| QKY617BBX5 |